| Note: This medical device record is a PMA supplement. A supplement may have changed the device description/function or indication from that approved in the original PMA. Be sure to look at the original PMA record for more information. |
| |
| Device | Edwards SAPIEN 3, SAPIEN 3 Ultra, and SAPIEN 3 Ultra RESILIA Transcatheter Heart Valve Systems |
|---|
| Generic Name | Prosthesis, mitral valve, percutaneously delivered |
|---|
| Applicant | EDWARDS LIFESCIENCES, LLC.
One Edwards Way
Irvine, CA 92614 |
|---|
| PMA Number | P140031 |
|---|
| Supplement Number | S162 |
|---|
| Date Received | 08/01/2023 |
|---|
| Decision Date | 05/23/2024 |
|---|
| Product Code |
NPU |
| Docket Number | 24M-2539 |
|---|
| Notice Date | 05/31/2024 |
|---|
| Advisory Committee |
Cardiovascular |
|---|
| Clinical Trials | NCT03193801
|
|---|
| Supplement Type | Panel Track |
|---|
| Supplement Reason | Labeling Change - Indications/instructions/shelf life/tradename |
|---|
| Expedited Review Granted? | No |
|---|
| Combination Product | No |
|---|
Approval Order Statement
The Edwards SAPIEN 3, SAPIEN 3 Ultra, and SAPIEN 3 Ultra RESILIA Transcatheter Heart Valve Systems are indicated for use in patients with symptomatic heart disease due to a failing (stenosed, insufficient, or combined) surgical bioprosthetic mitral valve who are judged by a heart team, including a cardiac surgeon, to be at intermediate or greater risk for open surgical therapy (i.e., predicted risk of surgical mortality >/=4% at 30 days, based on the Society of Thoracic Surgeons (STS) risk score and other clinical co-morbidities unmeasured by the STS risk calculator). |
| Approval Order | Approval Order |
|---|
| Summary | Summary of Safety and Effectiveness |
|---|
| Labeling | Labeling
|
|---|
| Post-Approval Study | Show Report Schedule and Study Progress |
|---|
|
|
